Latest News

10/31/2016

Genoscience Pharma to present data on its promising candidate GNS561 at the Liver meeting 2016- AASLD

Abstract: Background: In spite of successful approval and wide application of sorafenib, the prognosis for patients with...

06/03/2016

Genoscience Pharma to present data on its most promising candidate GNS561 at the 2016 ASCO Annual Meeting

Abstract: In spite of successful approval and wide application of sorafenib, the prognosis for patients with advanced...

02/25/2016

Cancer stem cells: Genoscience Pharma welcomes Pharmacyclics former senior management team to its board of directors

Marseille, February 24, 2016 – Genoscience Pharma, a biopharmaceutical company dedicated to discovering and developing...

07/30/2015

Genoscience Pharma to present data on its most promising candidate GNS561 at the Liver meeting 2015- AASLD

Abstract: Background: In spite of successful approval and wide application of sorafenib, the prognosis for patients with...

09/19/2014

26th EORTC-NCI-AACR SYMPOSIUM

Abstract: Despite efforts to understanding and treat acute myeloid leukemia (AML), there remains a need to more comprehensive...

07/30/2014

Oral treatment for Hepatitis C

BioLineRx Signs Exclusive License Agreement for BL-8020, an Oral Treatment for Hepatitis C BioLineRx (NASDAQ: BLRX; TASE:...

07/23/2014

Protease Inhibitors developement

RFS Pharma and Genoscience Pharma Sign Joint Venture Agreement to Discover and Develop Protease Inhibitors. RFS Pharma,...

07/23/2014

Worldwide License agreement for Hepatitis Inhibitor

RFS Pharma and Genoscience Enter Worldwide License Agreement with BioLineRx to Develop and Commercialize Hepatitis C Virus...

View all

Cancer Stems Cells

Despite significant time, money, and efforts expended on cancer research over the last half century, the contribution of newly developed therapeutics to improve patient survival has been limited, as these therapies have failed to prevent cancer...